Symetis

Symetis — the developer of devices founded in 2001 for low-invasive replacement of heart valves. The company proposes the solutions Acurate TA and Acurate neo. The headquarters of the company is in Lausanne (Switzerland), and production a predpryatiya — in Switzerland and Brazil. In the publication of March 30, 2017 the Reuters agency calls Symetis the world's fourth in value producer of the systems of transkateterny prosthetics of the aortal valve (TAVR).

2017: Boston Scientific buys Symetis for $435 million

At the end of March, 2017 the American producer of the medical equipment Boston Scientific announced purchase of Symetis for $435 million. Thanks to this acquisition the buyer hopes to strengthen the positions in Europe after a series of withdrawals of heart valves in the region.

The Acurate systems which offer Symetis will expand the range of TAVR products of Boston Scientific, having added them with new technologies of development of solutions for replacement of the aortal valve.

Logo of Symetis company

Symetis which since 2012 shows strong and steady growth at the level of 55% a year serves as demonstration as a success story in the structural warm market — the chairman of the board of directors of Symetis Dominik Ellenrieder comments on the transaction with Boston Scientific. — This purchase agreement is recognition of merits of Symetis in the field of research and development for satisfaction of needs of patients for the innovative cardiovascular technologies, know-how of the company and the strong relations with doctors and health workers.

Boston Scientific announced merger of Symetis nearly two months later after the declaration of a withdrawal of all transkateterny aortal Lotus valves in connection with a snapping mechanism problem.  The defect consisted in premature release of the pin connecting the valve to the delivery device.^[1]

Notes